Baxter BioScience Acquires Oncaspar® Portfolio for Leukemia

WASHINGTON - May 13, 2015 - PRLog -- Baxter is ready to expand its oncology segment by acquiring Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A for USD $900 million. Oncaspar is a biologic used as a part of a multi-agent chemotherapy regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL) a rapidly progressing cancer of the white blood cells. Baxter will also gain access to a related investigational biologic in development - calaspargase pegol, to treat ALL with an increased shelf life expected to reduce dosing frequency.

"Oncaspar is a  strong strategic fit for our rapidly expanding oncology business, as it complements our R&D programs in hematologic cancers," added David Meek, head of oncology for Baxter BioScience. "The acquisition provides an immediate commercial footprint in the United States and Europe with a heritage of expertise in treating this challenging disease."

Baxter intends to study Oncaspar for additional indications including ALL patient populations with significant unmet needs, as well as for acute myeloid leukemia (AML).

Oncaspar is currently marketed in the United States, Germany, Poland and other countries and has amassed annual sales revenue of approximately USD $100 million.The Oncaspar transaction is expected to close in the third quarter and will be marketed under Baxalta Incorporated – Baxter’s new biopharmaceutical division expected to be established by mid-year.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

This acquisition will certainly be beneficial to Baxter, as the company could accumulate $10 billion in revenue based on total market potential across oncology indications for its current pipeline assets. This will without a doubt bolster the need for both certified and qualified individuals to promote the company's diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they prefer individuals that are industry trained and have the background to promote their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to further develop meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.